Updated Jul 16, 2026
Chambers Rebecca has filed 2 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $2.35M.
Rebecca Chambers is the Chief Financial Officer at Veracyte, Inc., a genomic diagnostics company specializing in cancer diagnostics. She has been involved in multiple SEC filings related to her role within the company.
| Role | Chief Financial Officer |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-05 | VCYT | VERACYTE, INC. | S — Open-market sale | 2.0K | $50.09 | $98K |
| 2026-06-05 | VCYT | VERACYTE, INC. | S — Open-market sale | 1.6K | $49.28 | $79K |
| 2026-06-05 | VCYT | VERACYTE, INC. | F — Tax withholding / forfeiture | 3.7K | $47.80 | $177K |
| 2026-03-10 | VCYT | VERACYTE, INC. | A — Grant or award | 13.2K | $0.00 | |
| 2026-03-10 | VCYT | VERACYTE, INC. | A — Grant or award | 36.2K | $0.00 | |
| 2026-03-06 | VCYT | VERACYTE, INC. | S — Open-market sale [10b5-1] | 13.9K | $36.33 | $506K |
| 2026-03-06 | VCYT | VERACYTE, INC. | S — Open-market sale [10b5-1] | 4.4K | $35.55 | $156K |
| 2026-03-04 | VCYT | VERACYTE, INC. | F — Tax withholding / forfeiture | 7.2K | $36.01 | $260K |
| 2026-03-02 | VCYT | VERACYTE, INC. | F — Tax withholding / forfeiture | 12.0K | $38.75 | $467K |
| 2026-03-02 | VCYT | VERACYTE, INC. | A — Grant or award | 59.3K | $0.00 | |
| 2025-12-04 | VCYT | VERACYTE, INC. | S — Open-market sale [10b5-1] | 4.7K | $47.25 | $224K |
| 2025-12-04 | VCYT | VERACYTE, INC. | S — Open-market sale [10b5-1] | 8.5K | $46.61 | $398K |
| 2025-12-04 | VCYT | VERACYTE, INC. | F — Tax withholding / forfeiture [10b5-1] | 3.4K | $46.16 | $156K |
| 2025-09-02 | VCYT | VERACYTE, INC. | F — Tax withholding / forfeiture | 5.4K | $30.11 | $162K |
| 2024-12-04 | VCYT | VERACYTE, INC. | S — Open-market sale [10b5-1] | 7.0K | $43.23 | $303K |
| 2024-12-04 | VCYT | VERACYTE, INC. | F — Tax withholding / forfeiture [10b5-1] | 3.5K | $44.12 | $153K |
| 2024-11-14 | VCYT | VERACYTE, INC. | S — Open-market sale [10b5-1] | 15.3K | $38.34 | $586K |
Rebecca Chambers is the Chief Financial Officer at Veracyte, Inc., a genomic diagnostics company specializing in cancer diagnostics. She has been involved in multiple SEC filings related to her role within the company.…
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 8 open-market sales ($2.35M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Chambers Rebecca profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.